AstraZeneca selects Dotmatics platform
AstraZeneca’s Neuroscience Innovative Medicines Unit (iMed) has selected Dotmatics’ cloud based informatics platform as its research data management solution. The Dotmatics platform provides a single point of access to all data and functions across multidisciplinary groups. The platform includes compound registration and tracking, biological screening, DMPK analysis, fully integrated chemistry and biology ELN and project management to enable scientists, collaborators and partners to instantly interact with the same data regardless of location and time zone.
"We were seeking an enterprise data management solution that would be comprehensive and get us up and running from day one. Dotmatics platform gives us the ability to collaborate and share data easily, securely and in real time," said Dr. Mark Duggan, vice president of Neuroscience iMed.
The AstraZeneca Neuroscience iMed's strategy focuses on accessing science and capabilities through partnership and collaboration with academia, industry and CROs. The iMed manages a portfolio of drug discovery and development projects exclusively with external partners.
"We are excited to see the Dotmatics platform enabling and enriching the collaborative research capabilities of AstraZeneca's Neuroscience iMed," said Dr. Stephen Gallagher, chief executive officer of Dotmatics. "Today's industry demands modern informatics solutions to accommodate the different ways in which people work, internally or externally, with CROs or partners."